Is Eris Lifesciences a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Eris Lifesciences Ltd is a good quality company .

Is Eris Lifesciences undervalued or overvalued?

The key valuation ratios of Eris Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Eris Lifesciences share price return in the past 10 years?

Data is not available for this company

Is Eris Lifesciences a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Eris Lifesciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Eris Lifesciences Ltd - Stock Valuation and Financial Performance

Name: Eris Lifesciences
Brand: Eris Lifesciences

BSE: 540596 | NSE: ERIS | Pharmaceuticals & Drugs | Small Cap

Place order

Eris Lifesciences Share Price

₹1,320.65 32.95 2.56%
as on 31-Oct'24 16:01

10 Year X-Ray of Eris Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	49.3%	54.6%	62.6%	35.8%	26.5%	25.4%	27.6%	25.3%	17.3%	12.4%	-
Value Creation Index ⓘ	2.7	3.0	3.5	1.7	1.0	0.9	1.0	0.9	0.3	-0.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	546	597	750	856	982	1,074	1,212	1,347	1,685	2,009	2,485
Sales YoY Gr.	-	9.4%	25.5%	14.2%	14.8%	9.4%	12.8%	11.2%	25.1%	19.2%	-
Adj EPS ⓘ	6.3	9.6	16.7	20.2	21	21.6	26	30	27.8	28.6	25.6
YoY Gr.	-	51.4%	74.8%	20.5%	4.3%	2.7%	20.5%	15.3%	-7.1%	2.6%	-
BVPS (₹) ⓘ	19.3	21.7	41.3	62.6	83.6	95.3	115.8	140.3	161.3	189.8	203.6
Adj Net Profit ⓘ	86.9	132	230	277	289	293	353	408	379	388	348
Cash Flow from Ops. ⓘ	90.1	131	200	235	223	271	375	378	292	486	-
Debt/CF from Ops. ⓘ	0	0	0	1.6	0.8	0	0	0.1	2.9	5.6	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	15.6%	15.4%	18.4%	19.2%
Adj EPS ⓘ	18.2%	6.3%	3.2%	2.6%
BVPSⓘ	28.9%	17.8%	17.9%	17.7%
Share Price	-	25.6%	17.5%	52.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	39.2	46.5	53.1	38.8	28.7	24	24.6	23.4	18.5	16.2	13
Op. Profit Mgn % ⓘ	22.3	28.8	35.9	37.7	35.2	34.7	35.6	36.3	32	33.7	33.7
Net Profit Mgn % ⓘ	15.9	22.3	30.7	32.5	29.5	27.3	29.1	30.2	22	19.6	14
Debt to Equity ⓘ	0	0	0	0.4	0.2	0	0	0	0.4	1.1	0.7
Working Cap Days ⓘ	71	68	77	101	118	130	136	145	143	159	135
Cash Conv. Cycle ⓘ	8	12	11	-4	-4	7	14	13	29	30	-7

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 18.35%

Sales growth is good in last 4 quarters at 39.22%

Return on Equity has declined versus last 3 years average to 13.00%

Net Profit has been subdued in last 3 years 3.15%

Latest Financials - Eris Lifesciences Ltd.

	Standalone	Consolidated
TTM EPS (₹)	8.5	25.6
TTM Sales (₹ Cr.)	1,526	2,485
BVPS (₹.) ⓘ	189.3	203.6
Reserves (₹ Cr.) ⓘ	2,563	2,758
P/BV ⓘ	6.98	6.49
PE ⓘ	154.59	51.60

From the Market
52 Week Low / High (₹)	810.10 / 1521.05
All Time Low / High (₹)	341.05 / 1521.05
Market Cap (₹ Cr.)	17,980
Equity (₹ Cr.)	13.6
Face Value (₹)	1
Industry PE ⓘ	46.8

Management X-Ray of Eris Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

11.37

10.95

18.51

* Pledged shares as % of Promoter's holding (%)

Valuation of Eris Lifesciences

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Eris Lifesciences

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	546	597	749	856	982	1,074	1,212	1,347	1,685	2,009
Operating Expenses ⓘ	424	425	480	533	637	706	781	862	1,148	1,334
Manufacturing Costs	12	11	8	8	11	19	15	43	21	36
Material Costs	100	98	134	142	154	172	238	259	352	380
Employee Cost	126	125	131	157	191	206	229	250	346	404
Other Costs ⓘ	187	191	207	227	281	310	298	310	429	515
Operating Profit ⓘ	121	172	269	322	345	368	431	485	537	675
Operating Profit Margin (%)	22.3%	28.8%	35.9%	37.6%	35.1%	34.3%	35.5%	36.0%	31.9%	33.6%
Other Income ⓘ	3	3	25	26	32	16	9	26	11	24
Interest ⓘ	0	0	1	11	23	2	2	4	26	85
Depreciation ⓘ	16	20	23	26	36	50	43	65	117	183
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	109	154	270	312	317	331	394	442	405	431
Tax ⓘ	20	20	24	17	26	35	39	36	30	34
Profit After Tax	89	135	247	295	291	297	355	406	374	397
PAT Margin (%)	16.4%	22.6%	32.9%	34.5%	29.6%	27.6%	29.3%	30.1%	22.2%	19.8%
Adjusted EPS (₹)	6.5	9.7	18.0	21.4	21.2	21.8	26.2	29.9	28.1	28.8
Dividend Payout Ratio (%)	0%	62%	0%	0%	0%	13%	21%	20%	26%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	266	300	567	861	1,149	1,293	1,572	1,906	2,193	2,581
Share Capital ⓘ	0	0	14	14	14	14	14	14	14	14
Reserves ⓘ	266	299	553	848	1,136	1,280	1,559	1,893	2,180	2,568
Minority Interest	4	3	24	25	18	0	0	-0	25	636
Debt	1	0	0	274	0	0	0	45	699	1,966
Long Term Debt	1	0	0	274	0	0	0	45	644	655
Short Term Debt	0	0	0	0	0	0	0	0	55	1,311
Trade Payables	37	25	39	91	84	100	103	118	125	268
Others Liabilities ⓘ	47	64	102	177	229	43	28	44	430	1,368
Total Liabilities ⓘ	354	392	732	1,428	1,481	1,437	1,703	2,113	3,472	6,819
Fixed Assets
Gross Block	104	123	254	820	838	984	1,006	1,092	2,843	4,781
Accumulated Depreciation	32	52	23	48	78	109	152	174	275	454
Net Fixed Assetsⓘ	72	71	232	771	761	875	854	918	2,568	4,328
CWIP ⓘ	0	0	0	0	3	4	2	27	22	20
Investmentsⓘ	167	190	303	365	356	78	294	520	37	16
Inventories	58	48	56	65	83	69	94	118	131	189
Trade Receivables	24	25	49	67	84	157	140	161	293	422
Cash Equivalents	6	10	2	11	8	67	38	52	58	1,401
Others Assetsⓘ	29	48	90	149	187	186	280	316	363	444
Total Assets ⓘ	354	392	732	1,428	1,481	1,437	1,703	2,113	3,472	6,819

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	90	131	200	235	223	271	375	378	292	486
PBT ⓘ	109	154	270	312	317	331	394	442	405	431
Adjustment ⓘ	12	20	-1	14	31	44	44	49	140	254
Changes in Working Capital ⓘ	-8	-8	-16	-22	-53	-53	5	-30	-176	-99
Tax Paid ⓘ	-23	-35	-53	-70	-72	-52	-69	-83	-77	-101
Cash Flow From Investing Activity ⓘ	-92	-44	-184	-590	-5	123	-323	-320	-982	-1,855
Capex	-13	-24	-50	-25	-37	-146	-26	-120	-841	-129
Net Investments	-79	-21	-135	-38	35	288	-295	-188	-165	-518
Others ⓘ	0	0	0	-527	-3	-19	-3	-11	24	-1,207
Cash Flow From Financing Activityⓘ	0	-84	-24	363	-221	-335	-82	-45	688	1,380
Net Proceeds from Shares ⓘ	0	0	0	0	1	0	0	7	2	5
Net Proceeds from Borrowing ⓘ	0	-1	-7	373	-200	-176	0	45	785	1,464
Interest Paid ⓘ	0	0	0	-10	-22	-2	-2	-4	-23	-77
Dividend Paid ⓘ	0	-83	-17	0	0	-47	-75	-82	-100	0
Others ⓘ	0	0	0	0	0	-110	-6	-11	24	-11
Net Cash Flow ⓘ	-2	4	-8	8	-3	60	-30	14	-2	11

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	40.3	47.68	56.9	41.3	28.96	24.28	24.78	23.33	18.25	16.63
ROCE (%)	49.25	54.56	62.56	35.76	26.54	25.44	27.6	25.29	17.3	12.36
Asset Turnover Ratio	1.78	1.65	1.33	0.79	0.68	0.74	0.79	0.73	0.63	0.41
PAT to CFO Conversion(x)	1.01	0.97	0.81	0.8	0.77	0.91	1.06	0.93	0.78	1.22
Working Capital Days
Receivable Days	15	15	18	25	28	41	44	39	47	62
Inventory Days	34	31	25	26	28	26	24	28	26	28
Payable Days	136	114	86	167	208	196	155	156	126	189

Eris Lifesciences Ltd Stock News

Eris Lifesciences Ltd FAQs

What is the share price of Eris Lifesciences?

Company share prices are keep on changing according to the market conditions. The closing price of Eris Lifesciences on 31-Oct-2024 16:01 is ₹1,320.7.

What is the market cap of Eris Lifesciences?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Oct-2024 16:01 the market cap of Eris Lifesciences stood at ₹17,979.6.

What is the P/E ratio of Eris Lifesciences?

The latest P/E ratio of Eris Lifesciences as of 31-Oct-2024 16:01 is 154.6.

What is the P/B ratio of Eris Lifesciences?

The latest P/B ratio of Eris Lifesciences as of 31-Oct-2024 16:01 is 6.98.

What is the 52-week high and low of Eris Lifesciences?

The 52-week high of Eris Lifesciences is ₹1,521.1 and the 52-week low is ₹810.1.

What is the TTM revenue of Eris Lifesciences?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Eris Lifesciences is ₹1,526 ( Cr.) .

About Eris Lifesciences Ltd

Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.

The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.

The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.

Business area of the company

The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.

History and milestones

2007: Incorporation of the company.
2007: Launched “Eris” division focused on cardiology and diabetes segment.
2008: Launched “Nikkos” division focused on gastroenterology and orthopedics segment.
2009: Launched “Adura” division focused on cardiology and diabetes segment.
2011: Launched “Montana” division focused on gynecology and pediatrics segment.
2012: Launched “Inspira” division focused on cardiology segment.
2014: Launched “Victus” division focused on anti-diabetes segment.
2014: Set up Assam Facility by the company.
2015: Launched “Eris 2” division focused on pain management segment.
2016: Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited).
2016: Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
2016: Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
2017: Acquired the trademarks ‘UNION’, ‘REUNION’ and ‘BON UNION’.
2017: Eris acquires 40 trademarks from Amay Pharma
2017: Eris acquires Pune based UTH Healthcare.
2018: Eris entered into a distribution agreement with India Medtronic Private Limited.
2019: Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn.
2019: Eris partners with Pharmanutra S.P.A of Italy for Sideral.